In order to promote the construction and development of hematologic oncology, improve the clinical scientific research level of hematologic oncology physicians at the grass-roots level, and promote the application of new technologies and cutting-edge medical technologies, the "First Founding Conference and Academic Conference of Hematologic Oncology Professional Committee" co-sponsored by Sichuan Provincial People's Hospital and Chengdu High-tech Medical Association was successfully held online from May 20 to 21, 2022.

On the evening of May 20, 111 hematologic tumor experts from Sichuan and Chongqing met in the cloud and held the first hematologic tumor committee establishment meeting. According to the Articles of Association of Hi-tech Medical Association and the relevant provisions of the Academic Organization Management Measures, the congress passed deliberation and democratically elected the Standing Committee, the chairman, the vice chairman and other new leaders. Huang Xiaobing, Director of Sichuan Provincial People's Hospital, was appointed as the honorary chairman, and Li Hui, director of Sichuan Provincial People's Hospital, was elected as the chairman. Chen Jiao, Director of Sichuan Provincial People's Hospital; Huang Jie, Director of West China Hospital of Sichuan University; Sun Yi, Director of Western Theater Command Air Force Hospital; Tan Jing, director of Chengdu Third People's Hospital; Wang Xin, Director of Suining Central Hospital; Xiao Jian, Director of Zigong First People's Hospital; Xu Fang, Director of Mianyang Central Hospital; Yang Lihua, Director of Dazhou Central Hospital; Yuan Ying, Director of Guangyuan Central Hospital of Sichuan Province; North Sichuan Zou Xingli, director of the Affiliated Hospital of the Medical College, was elected as vice chairman. Lin Fan, deputy secretary-general of Chengdu High-tech Medical Association, attended the meeting online and delivered a speech.

Li Hui, the newly elected chairman, said that the establishment of the hematologic oncology Committee of Chengdu High-tech Medical Association will form an effective academic exchange network and promote the research and exchange in the field of hematology in Sichuan. Based on high and new technology, to form an authoritative hematology hub; Sitting in Chengdu, to provide effective support for the treatment of blood diseases in Sichuan; Influence the west and promote regional research and technological progress; Look across the country to make beneficial contributions for our country's blood diseases research.

(Speech by newly elected Chairwoman Li Hui)

(Speech by Lin Fan, Deputy Secretary-General)

 With the purpose of actively promoting the standardized diagnosis and treatment of hematologic tumors, striving to promote interdisciplinary collaboration and integration, and encouraging the promotion and application of innovative research and new technologies, this annual conference will integrate more cutting-edge ideas into it. 47 experts and scholars brought wonderful academic sharing. The speakers taught each other with all their resources, shared the academic feast with the online delegates, bathed in the blue sea of wisdom. Through various cutting-edge topics, focused on "basic research", looked for scientific problems, and clarified the research ideas; Pay attention to "clinical research", talk about research perception, share innovative results; It promoted the "transformation of achievements" and built an academic exchange platform for fellow scholars from all over the country, attracting 20,000 viewers and listeners.

Finally, the chairman of the conference, Li Hui, made a concluding speech, she said: hearing the road has been successively, specialized. By sharing and exchanging academic findings and achievements, we can better understand the latest research progress, so as to choose the best treatment plan in clinical treatment, and promote the rapid development of the field of blood diseases.

As doctors, we have a more important and arduous responsibility. We will unite as one and work together to make contributions to the research and prevention of blood diseases.